BNP Paribas Discount Zert SNW 25..../ DE000PC3XEB4 /
16/05/2024 18:20:36 | Chg.-0.150 | Bid16/05/2024 | Ask16/05/2024 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
77.170EUR | -0.19% | 77.170 Bid Size: 600 |
78.090 Ask Size: 600 |
SANOFI SA INHABER ... | - EUR | 25/09/2025 | Call |
GlobeNewswire
14:00
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients wit...
GlobeNewswire
13/05
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...
GlobeNewswire
13/05
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
13/05
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
10/05
Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...
GlobeNewswire
08/05
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
07/05
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
02/05
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant R...
GlobeNewswire
25/04
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
GlobeNewswire
23/04
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia